Experimental drug rigosertib tested against aggressive skin cancer in rare disease patients
NCT ID NCT03786237
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small early-phase trial tested an experimental drug called rigosertib in just 2 people with a rare blistering skin disease (recessive dystrophic epidermolysis bullosa) who also had advanced skin cancer. The goal was to see if the drug could shrink tumors and whether it was safe. Rigosertib was given as oral capsules or intravenous infusions. Because only 2 patients took part, the results are very limited and cannot be generalized.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rigosertib (oral capsules or intravenous infusion)
What this could lead to
If it works, this could point toward a treatment for advanced skin cancer in people with recessive dystrophic epidermolysis bullosa.
What could go wrong
This is a very small, early-phase trial with only 2 patients, so results may not apply to others. The drug may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EB House Austria/Dept. of Dermatology University Hospital
Salzburg, State of Salzburg, 5020, Austria